Advisor Group Holdings, Inc. Allogene Therapeutics, Inc. Transaction History

Advisor Group Holdings, Inc.

$52.6 Billion
Q2 2025

A detailed history of Advisor Group Holdings, Inc. transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 40,466 shares of ALLO stock, worth $42,489. This represents 0.0% of its overall portfolio holdings.

Number of Shares

40,466

Previous 20,026 102.07%

Holding current value

$42,489

Previous $22,000 104.55%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Sep 04, 2025	BUY	$0.95 - $1.7 $19,418 - $34,748	20,440 Added 102.07%	40,466 $45,000
Q2 2025 Aug 13, 2025	SELL	$0.95 - $1.7 $12,325 - $22,055	-12,974 Reduced 39.32%	20,026 $22,000
Q1 2025 May 12, 2025	BUY	$1.4 - $2.84 $19,754 - $40,072	14,110 Added 74.7%	33,000 $48,000
Q4 2024 Jun 06, 2025	SELL	$1.84 - $3.22 $22,650 - $39,638	-12,310 Reduced 37.3%	20,690 $44,000
Q4 2024 Feb 07, 2025	BUY	$1.84 - $3.22 $809 - $1,416	440 Added 2.38%	18,890 $40,000
Q3 2024 Nov 13, 2024	SELL	$2.08 - $3.5 $626 - $1,053	-301 Reduced 1.61%	18,450 $51,000
Q2 2024 Aug 13, 2024	BUY	$2.23 - $4.38 $18,636 - $36,603	8,357 Added 80.4%	18,751 $43,000
Q1 2024 May 10, 2024	SELL	$2.92 - $5.63 $4,686 - $9,036	-1,605 Reduced 13.38%	10,394 $46,000
Q4 2023 Feb 12, 2024	SELL	$2.28 - $3.5 $458 - $703	-201 Reduced 1.65%	11,999 $38,000
Q3 2023 Nov 13, 2023	BUY	$3.17 - $5.96 $27,832 - $52,328	8,780 Added 256.73%	12,200 $38,000
Q2 2023 Aug 10, 2023	SELL	$4.53 - $6.74 $21,494 - $31,981	-4,745 Reduced 58.11%	3,420 $16,000
Q1 2023 May 12, 2023	SELL	$4.92 - $8.21 $21,761 - $36,312	-4,423 Reduced 35.14%	8,165 $40,000
Q4 2022 Feb 10, 2023	SELL	$5.62 - $11.11 $31,028 - $61,338	-5,521 Reduced 30.49%	12,588 $79,000
Q3 2022 Nov 14, 2022	SELL	$10.32 - $17.28 $98,339 - $164,661	-9,529 Reduced 34.48%	18,109 $196,000
Q2 2022 Aug 10, 2022	BUY	$6.78 - $12.28 $110,310 - $199,795	16,270 Added 143.12%	27,638 $315,000
Q1 2022 May 04, 2022	BUY	$7.65 - $15.29 $7,642 - $15,274	999 Added 9.63%	11,368 $103,000
Q3 2021 Nov 05, 2021	BUY	$21.01 - $27.64 $46,873 - $61,664	2,231 Added 27.41%	10,369 $266,000
Q2 2021 Aug 02, 2021	BUY	$23.49 - $35.8 $49,493 - $75,430	2,107 Added 34.94%	8,138 $212,000
Q1 2021 May 13, 2021	BUY	$25.79 - $39.02 $48,020 - $72,655	1,862 Added 44.66%	6,031 $214,000
Q4 2020 Feb 10, 2021	BUY	$25.24 - $43.45 $59,793 - $102,933	2,369 Added 131.61%	4,169 $105,000
Q3 2020 Nov 12, 2020	BUY	$32.38 - $44.96 $4,015 - $5,575	124 Added 7.4%	1,800 $68,000
Q2 2020 Aug 14, 2020	SELL	$18.39 - $54.04 $18 - $54	-1 Reduced 0.06%	1,676 $72,000
Q1 2020 May 18, 2020	BUY	$18.22 - $28.25 $30,554 - $47,375	1,677 New	1,677 $33,000

Others Institutions Holding ALLO

# of Institutions

169

Shares Held

160M

Call Options Held

146K

Put Options Held

97.1K

View Full List

About Allogene Therapeutics, Inc.

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $151M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

More about ALLO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.

Account

Advisor Group Holdings, Inc. Allogene Therapeutics, Inc. Transaction History